DigitalCFO Newsroom | 31 January 2022
Christina Manfre will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs.
Christina Manfre, a partner at PKF Sydney, will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs. Race Oncology Ltd expects to enhance its financial capabilities through the appointment of Christina Manfre as chief financial officer. Manfre is a partner at PKF Sydney Pty Ltd and through PKF will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs.
Wealth Of Experience
RAC, an ASX listed precision oncology company, expects to benefit from the new CFO’s wealth of experience working with a diverse range of clients. Manfre’s professional affiliations and experience include a Bachelor of Commerce with Applied Finance, member of Chartered Accountants (ANZ) and is a member of the Australian Institute of Company Directors (AICD).
Higher Shares
Shares today have been as much as 4.1% higher to A$3.05 while the company’s market cap is approximately A$484.71 million. Race Oncology has a Phase 2/3 cancer drug called Zantrene®, a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.
‘Three Pillar’ Strategy
Race is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The company is pursuing commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene®.
In breakthrough preclinical research, Race has also discovered that Zantrene® protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.
The company also has compelling clinical data for Zantrene® as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).
Source: Proactive Investors, John Miller
